Altimmune, Inc. (FRA:3G0)
4.451
+0.178 (4.17%)
At close: Dec 5, 2025
Altimmune Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 61.24 | 36.93 | 135.12 | 111.1 | 190.3 | 115.92 | Upgrade
|
| Short-Term Investments | 149.54 | 94.97 | 62.7 | 73.78 | - | 100.01 | Upgrade
|
| Cash & Short-Term Investments | 210.78 | 131.89 | 197.82 | 184.88 | 190.3 | 215.92 | Upgrade
|
| Cash Growth | 51.22% | -33.33% | 7.00% | -2.85% | -11.87% | 479.81% | Upgrade
|
| Accounts Receivable | 0.15 | 0.54 | 1.11 | 0.17 | 0.43 | 4.61 | Upgrade
|
| Other Receivables | 1.25 | 2.57 | 3.74 | 2.37 | 5.41 | 7.76 | Upgrade
|
| Receivables | 1.39 | 3.12 | 4.85 | 2.54 | 5.84 | 12.37 | Upgrade
|
| Prepaid Expenses | 4.31 | 2.1 | 6.92 | 5.36 | 7.95 | 1.93 | Upgrade
|
| Restricted Cash | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | Upgrade
|
| Other Current Assets | 0.1 | 0.1 | - | - | - | - | Upgrade
|
| Total Current Assets | 216.62 | 137.25 | 209.63 | 192.81 | 204.13 | 230.26 | Upgrade
|
| Property, Plant & Equipment | 1.83 | 2.05 | 1.01 | 1.68 | 2.25 | 1.96 | Upgrade
|
| Other Intangible Assets | - | - | - | 12.42 | 12.42 | 12.82 | Upgrade
|
| Other Long-Term Assets | - | - | - | 0.02 | 0.07 | 0.07 | Upgrade
|
| Total Assets | 218.45 | 139.31 | 210.64 | 206.93 | 218.87 | 245.12 | Upgrade
|
| Accounts Payable | 4.8 | 0.21 | 2.07 | 4.8 | 2.03 | 0.61 | Upgrade
|
| Accrued Expenses | 7.56 | 9.98 | 9.58 | 10.63 | 9.74 | 11.05 | Upgrade
|
| Current Portion of Leases | 0.25 | 0.28 | 0.5 | 0.45 | 0.41 | 0.36 | Upgrade
|
| Current Income Taxes Payable | - | - | - | 1.17 | - | - | Upgrade
|
| Other Current Liabilities | - | - | - | - | 6.09 | - | Upgrade
|
| Total Current Liabilities | 12.61 | 10.47 | 12.14 | 17.05 | 18.28 | 12.02 | Upgrade
|
| Long-Term Debt | 14.45 | - | - | - | - | - | Upgrade
|
| Long-Term Leases | 1.21 | 1.4 | 0.18 | 0.67 | 1.12 | 1.47 | Upgrade
|
| Long-Term Unearned Revenue | 0.16 | 0.16 | 0.16 | 0.25 | 0.25 | 0.25 | Upgrade
|
| Other Long-Term Liabilities | 4.42 | 3.77 | 4.06 | 3.66 | 0.08 | 5.5 | Upgrade
|
| Total Liabilities | 32.85 | 15.8 | 16.54 | 21.64 | 19.73 | 19.24 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 812.73 | 689.86 | 665.43 | 568.4 | 497.34 | 417.34 | Upgrade
|
| Retained Earnings | -622.13 | -561.39 | -466.33 | -377.88 | -293.17 | -186.42 | Upgrade
|
| Comprehensive Income & Other | -5.02 | -4.97 | -5 | -5.23 | -5.04 | -5.04 | Upgrade
|
| Total Common Equity | 185.6 | 123.51 | 194.1 | 185.29 | 199.14 | 225.88 | Upgrade
|
| Shareholders' Equity | 185.6 | 123.51 | 194.1 | 185.29 | 199.14 | 225.88 | Upgrade
|
| Total Liabilities & Equity | 218.45 | 139.31 | 210.64 | 206.93 | 218.87 | 245.12 | Upgrade
|
| Total Debt | 15.91 | 1.68 | 0.67 | 1.12 | 1.54 | 1.82 | Upgrade
|
| Net Cash (Debt) | 194.87 | 130.21 | 197.14 | 183.76 | 188.77 | 214.1 | Upgrade
|
| Net Cash Growth | 41.61% | -33.95% | 7.29% | -2.65% | -11.83% | 503.16% | Upgrade
|
| Net Cash Per Share | 2.45 | 1.83 | 3.70 | 3.92 | 4.57 | 8.35 | Upgrade
|
| Filing Date Shares Outstanding | 104.25 | 77.01 | 70.9 | 49.28 | 42.92 | 36.98 | Upgrade
|
| Total Common Shares Outstanding | 95.6 | 72.35 | 70.68 | 49.2 | 40.69 | 36.97 | Upgrade
|
| Working Capital | 204.01 | 126.79 | 197.48 | 175.76 | 185.85 | 218.24 | Upgrade
|
| Book Value Per Share | 1.94 | 1.71 | 2.75 | 3.77 | 4.89 | 6.11 | Upgrade
|
| Tangible Book Value | 185.6 | 123.51 | 194.1 | 172.87 | 186.72 | 213.05 | Upgrade
|
| Tangible Book Value Per Share | 1.94 | 1.71 | 2.75 | 3.51 | 4.59 | 5.76 | Upgrade
|
| Machinery | - | 0.7 | 0.7 | 0.65 | 1.55 | 1.31 | Upgrade
|
| Leasehold Improvements | - | 1.75 | 1.75 | 1.75 | 1.79 | 1.29 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.